Drug Discovery Looks for Its Next Fix

By Michael Feldman

July 31, 2012

Despite the highly profitable nature of the pharmaceutical business and the large amount of R&D money companies throw at creating new medicines, the pace of drug development is agonizingly slow.  Over the last few years, on average, less than two dozen new drugs have been introduced per year. One of the more promising technologies that could help speed up this process is supercomputing, which can be used not only to find better, safer drugs, but also to weed out those compounds that would eventually fail during the latter stages of drug trials.

According to a 2010 report in Nature, big pharma spends something like $50 billion per year on drug research and development. (To put that in perspective, that’s four to five times the total spend for high performance computing.) The Nature report estimates the price tag to bring a drug successfully to market is about $1.8 billion, and rising. A lot of that cost is due to the high attrition rate of drugs, which is caused by problems in absorption, distribution, metabolism, excretion and toxicity that gets uncovered during clinical trials.

Ideally, the drug makers would like know which compounds were going to succeed before they got to the expensive stages of development. That’s where high performance computing can help. The approach is to use molecular docking simulations on the computer to determine if the drug candidate can bind to the target protein associated with the disease. The general idea is to find the key (the small molecule drug) that fits in the lock (the protein).

AutoDock, probably the most common molecular modeling application for protein docking, is a one of the more popular software package used by the drug research community. It played a role in developing some of the more successful HIV drugs on the market. Fortunately, AutoDock is freely available under the GNU General Public License.

The trick is to do these docking simulations on a grand scale. Thanks to the power of modern HPC machines, millions of compounds can now be screened against a protein in a reasonable amount of time. In truth, that timeframe is dependent upon how many cores you can put to the task. For a typical medium-sized cluster that a drug company might have in-house, it would take several weeks to screen just a few thousand compounds against one target protein. To reach a more interactive workflow, you need a something approaching a petascale supercomputer.

But not necessarily an actual supercomputer. Compute clouds have turned out to be very suitable for this type of embarrassing parallel application. For example, in a recent test with 50,000 cores on Amazon’s cloud (provisioned by Cycle Computing), software was able to screen 21 million compounds against a protein target in less than three hours.

Real supercomputers work too. At Oak Ridge National Lab (ORNL), researchers there used 50,000 cores of Jaguar to screen about 10 million drug candidates in less than a day. Jeremy C. Smith, director of the Center for Molecular Biophysics at ORNL, believes his type level of virtual screening is the most cost-effective approach to turbo-charge the drug pipeline. But the real utility of the supercomputing approach, says Smith, is that it can also be used to screen out drugs with toxic side effects.

Toxicity is often hard to detect until it comes time to do clinical trials, the most expensive and time-consuming phase of drug development. Worse yet, sometimes toxicity is not discovered until after the drug has been approved and released into the wild. So identifying these compounds early has the potential to save lots of money, not to mention lives. As Smith says, “If drug candidates are going to fail, you want them to fail fast, fail cheap.”

At the molecular level, toxicity is caused by a drug binding to the wrong protein, one that is actually needed by the body, rather than just selectively binding to the protein causing the condition. The problem is humans have about a thousand proteins, so every potential compound needs to be checked against each one. When you’re working with millions of drug candidates, the job becomes overwhelming, even for the petaflop supercomputers of today. To support the toxicity problem, you’ll need an exascale machine, says Smith.

Besides screening for toxicity, the same exascale setup can be used to repurpose existing drugs for other medical conditions. That is, the drug docking software could use approved drugs as the starting point and try to match them against various target proteins know to cause disease. Right now, drug repurposing is typically discovered on a trial-and-error basis, but the increasing number of compounds that are now in this multiple-use category suggests this could be rich new area of drug discovery.

In any case, sheer compute power is not the complete answer. For starters, the software has to be scaled up to the level of the hardware, and on an exascale machine, that hardware is more than likely going to be based on heterogenous processors. But since the problem is easily parallelized (each docking operation can be performed independently of one another), at least the scaling aspect should be relatively easy to overcome.

The larger problem is that the molecular modeling software itself is imperfect. Unlike a true lock and key, proteins are dynamic structures, and the action of binding to a molecule changes their shape. Therefore, physics simulation is also required to get a more precise match.

AutoDock, for example, is only able to provide a crude match between drug and protein. To get higher fidelity docking, more compute-intensive algorithms are required. Researchers, like those at ORNL, often resort to more precise molecular dynamics codes after getting performing a crude screening run with AutoDock.

None of this is a guarantee that virtual docking on exascale machines is going to launch a golden age of drugs. It’s possible that researchers will discover that there are just a handful of small molecule compounds that actually exhibit both disease efficacy and are non-toxic. But Smith believes this approach is full of promise. “This is the way to design drugs since this mirrors the way nature works,” he says.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

UCSD, AIST Forge Tighter Alliance with AI-Focused MOU

January 18, 2018

The rich history of collaboration between UC San Diego and AIST in Japan is getting richer. The organizations entered into a five-year memorandum of understanding on January 10. The MOU represents the continuation of a 1 Read more…

By Tiffany Trader

New Blueprint for Converging HPC, Big Data

January 18, 2018

After five annual workshops on Big Data and Extreme-Scale Computing (BDEC), a group of international HPC heavyweights including Jack Dongarra (University of Tennessee), Satoshi Matsuoka (Tokyo Institute of Technology), Read more…

By John Russell

Researchers Measure Impact of ‘Meltdown’ and ‘Spectre’ Patches on HPC Workloads

January 17, 2018

Computer scientists from the Center for Computational Research, State University of New York (SUNY), University at Buffalo have examined the effect of Meltdown and Spectre security updates on the performance of popular H Read more…

By Tiffany Trader

HPE Extreme Performance Solutions

HPE and NREL Take Steps to Create a Sustainable, Energy-Efficient Data Center with an H2 Fuel Cell

As enterprises attempt to manage rising volumes of data, unplanned data center outages are becoming more common and more expensive. As the cost of downtime rises, enterprises lose out on productivity and valuable competitive advantage without access to their critical data. Read more…

Fostering Lustre Advancement Through Development and Contributions

January 17, 2018

Six months after organizational changes at Intel's High Performance Data (HPDD) division, most in the Lustre community have shed any initial apprehension around the potential changes that could affect or disrupt Lustre Read more…

By Carlos Aoki Thomaz

UCSD, AIST Forge Tighter Alliance with AI-Focused MOU

January 18, 2018

The rich history of collaboration between UC San Diego and AIST in Japan is getting richer. The organizations entered into a five-year memorandum of understandi Read more…

By Tiffany Trader

New Blueprint for Converging HPC, Big Data

January 18, 2018

After five annual workshops on Big Data and Extreme-Scale Computing (BDEC), a group of international HPC heavyweights including Jack Dongarra (University of Te Read more…

By John Russell

Researchers Measure Impact of ‘Meltdown’ and ‘Spectre’ Patches on HPC Workloads

January 17, 2018

Computer scientists from the Center for Computational Research, State University of New York (SUNY), University at Buffalo have examined the effect of Meltdown Read more…

By Tiffany Trader

Fostering Lustre Advancement Through Development and Contributions

January 17, 2018

Six months after organizational changes at Intel's High Performance Data (HPDD) division, most in the Lustre community have shed any initial apprehension aroun Read more…

By Carlos Aoki Thomaz

When the Chips Are Down

January 11, 2018

In the last article, "The High Stakes Semiconductor Game that Drives HPC Diversity," I alluded to the challenges facing the semiconductor industry and how that may impact the evolution of HPC systems over the next few years. I thought I’d lift the covers a little and look at some of the commercial challenges that impact the component technology we use in HPC. Read more…

By Dairsie Latimer

How Meltdown and Spectre Patches Will Affect HPC Workloads

January 10, 2018

There have been claims that the fixes for the Meltdown and Spectre security vulnerabilities, named the KPTI (aka KAISER) patches, are going to affect applicatio Read more…

By Rosemary Francis

Momentum Builds for US Exascale

January 9, 2018

2018 looks to be a great year for the U.S. exascale program. The last several months of 2017 revealed a number of important developments that help put the U.S. Read more…

By Alex R. Larzelere

ANL’s Rick Stevens on CANDLE, ARM, Quantum, and More

January 8, 2018

Late last year HPCwire caught up with Rick Stevens, associate laboratory director for computing, environment and life Sciences at Argonne National Laboratory, f Read more…

By John Russell

Inventor Claims to Have Solved Floating Point Error Problem

January 17, 2018

"The decades-old floating point error problem has been solved," proclaims a press release from inventor Alan Jorgensen. The computer scientist has filed for and Read more…

By Tiffany Trader

US Coalesces Plans for First Exascale Supercomputer: Aurora in 2021

September 27, 2017

At the Advanced Scientific Computing Advisory Committee (ASCAC) meeting, in Arlington, Va., yesterday (Sept. 26), it was revealed that the "Aurora" supercompute Read more…

By Tiffany Trader

Japan Unveils Quantum Neural Network

November 22, 2017

The U.S. and China are leading the race toward productive quantum computing, but it's early enough that ultimate leadership is still something of an open questi Read more…

By Tiffany Trader

AMD Showcases Growing Portfolio of EPYC and Radeon-based Systems at SC17

November 13, 2017

AMD’s charge back into HPC and the datacenter is on full display at SC17. Having launched the EPYC processor line in June along with its MI25 GPU the focus he Read more…

By John Russell

Nvidia Responds to Google TPU Benchmarking

April 10, 2017

Nvidia highlights strengths of its newest GPU silicon in response to Google's report on the performance and energy advantages of its custom tensor processor. Read more…

By Tiffany Trader

IBM Begins Power9 Rollout with Backing from DOE, Google

December 6, 2017

After over a year of buildup, IBM is unveiling its first Power9 system based on the same architecture as the Department of Energy CORAL supercomputers, Summit a Read more…

By Tiffany Trader

Fast Forward: Five HPC Predictions for 2018

December 21, 2017

What’s on your list of high (and low) lights for 2017? Volta 100’s arrival on the heels of the P100? Appearance, albeit late in the year, of IBM’s Power9? Read more…

By John Russell

Chip Flaws ‘Meltdown’ and ‘Spectre’ Loom Large

January 4, 2018

The HPC and wider tech community have been abuzz this week over the discovery of critical design flaws that impact virtually all contemporary microprocessors. T Read more…

By Tiffany Trader

Leading Solution Providers

Perspective: What Really Happened at SC17?

November 22, 2017

SC is over. Now comes the myriad of follow-ups. Inboxes are filled with templated emails from vendors and other exhibitors hoping to win a place in the post-SC thinking of booth visitors. Attendees of tutorials, workshops and other technical sessions will be inundated with requests for feedback. Read more…

By Andrew Jones

Tensors Come of Age: Why the AI Revolution Will Help HPC

November 13, 2017

Thirty years ago, parallel computing was coming of age. A bitter battle began between stalwart vector computing supporters and advocates of various approaches to parallel computing. IBM skeptic Alan Karp, reacting to announcements of nCUBE’s 1024-microprocessor system and Thinking Machines’ 65,536-element array, made a public $100 wager that no one could get a parallel speedup of over 200 on real HPC workloads. Read more…

By John Gustafson & Lenore Mullin

Researchers Measure Impact of ‘Meltdown’ and ‘Spectre’ Patches on HPC Workloads

January 17, 2018

Computer scientists from the Center for Computational Research, State University of New York (SUNY), University at Buffalo have examined the effect of Meltdown Read more…

By Tiffany Trader

Delays, Smoke, Records & Markets – A Candid Conversation with Cray CEO Peter Ungaro

October 5, 2017

Earlier this month, Tom Tabor, publisher of HPCwire and I had a very personal conversation with Cray CEO Peter Ungaro. Cray has been on something of a Cinderell Read more…

By Tiffany Trader & Tom Tabor

Flipping the Flops and Reading the Top500 Tea Leaves

November 13, 2017

The 50th edition of the Top500 list, the biannual publication of the world’s fastest supercomputers based on public Linpack benchmarking results, was released Read more…

By Tiffany Trader

How Meltdown and Spectre Patches Will Affect HPC Workloads

January 10, 2018

There have been claims that the fixes for the Meltdown and Spectre security vulnerabilities, named the KPTI (aka KAISER) patches, are going to affect applicatio Read more…

By Rosemary Francis

GlobalFoundries, Ayar Labs Team Up to Commercialize Optical I/O

December 4, 2017

GlobalFoundries (GF) and Ayar Labs, a startup focused on using light, instead of electricity, to transfer data between chips, today announced they've entered in Read more…

By Tiffany Trader

HPC Chips – A Veritable Smorgasbord?

October 10, 2017

For the first time since AMD's ill-fated launch of Bulldozer the answer to the question, 'Which CPU will be in my next HPC system?' doesn't have to be 'Whichever variety of Intel Xeon E5 they are selling when we procure'. Read more…

By Dairsie Latimer

  • arrow
  • Click Here for More Headlines
  • arrow
Share This